• Baseline A1C ∼ 8%
  • Reference [3]
Canagliflozin (Can) monotherapy,
26-week, placebo-controlled trial
Placebo
(N=192)
Can 100 mg daily
(N=195)
Can 300 mg daily
(N=197)
Hg A1C (%)
(change from baseline)
+0.14 -0.77 -1.03
  • Baseline A1C ∼ 8%
  • Metformin dose ≥ 1500 mg/day in all patients
  • Reference [3]
Canagliflozin (Can) added to metformin
26-week, placebo-controlled trial
Placebo
(N=183)
Can 100 mg daily
(N=368)
Can 300 mg daily
(N=367)
Hg A1C (%)
(change from baseline)
-0.17 -0.79 -0.94
  • Baseline A1C ∼ 7.9%
  • Reference [6]
Dapagliflozin (Dap) monotherapy,
24-week, placebo-controlled trial
Placebo
(N=75)
Dap 5 mg daily
(N=64)
Dap 10 mg daily
(N=70)
Hg A1C (%)
(change from baseline)
-0.2 -0.8 -0.9
  • Baseline A1C ∼ 8%
  • Metformin dose ≥ 1500 mg/day in all patients
  • Reference [6]
Dapagliflozin (Dap) added to metformin
24-week, placebo-controlled trial
Placebo
(N=137)
Dap 5 mg daily
(N=137)
Dap 10 mg daily
(N=135)
Hg A1C (%)
(change from baseline)
-0.3 -0.7 -0.8

  • Baseline A1C - 7.9%
  • Reference [7]
Empagliflozin (Emp) monotherapy,
24-week, placebo-controlled trial
Placebo
(N=228)
Emp 10 mg daily
(N=224)
Emp 25 mg daily
(N=224)
Hg A1C (%)
(change from baseline)
+0.1 -0.7 -0.8
  • Baseline A1C - 7.9%
  • Metformin dose ≥ 1500 mg/day in all patients
  • Reference [7]
Empagliflozin (Emp) added to metformin
24-week, placebo-controlled trial
Placebo
(N=207)
Emp 10 mg daily
(N=217)
Emp 25 mg daily
(N=213)
Hg A1C (%)
(change from baseline)
-0.1 -0.7 -0.8




  • Reference [2]
Placebo-controlled trials with canagliflozin
Side Effect Canagliflozin
(% of patients)
Placebo
(% of patients)
Female yeast infection 10 - 12% 3%
Male yeast infection 3.5 - 4.5% 0.6%

  • Reference [6]
Placebo-controlled trials with dapagliflozin (Dap)
Side Effect Dap 5 mg
(% of patients)
Dap 10 mg
(% of patients)
Placebo
(% of patients)
Female yeast infection 8.4% 6.9% 1.5%
Male yeast infection 2.8% 2.7% 0.3%

  • Reference [7]
Placebo-controlled trials with empagliflozin (Emp)
Side Effect Emp 10 mg
(% of patients)
Emp 25 mg
(% of patients)
Placebo
(% of patients)
Female yeast infection 5.4% 6.4% 1.5%
Male yeast infection 3.1% 1.6% 0.4%

  • Reference [2]
Placebo-controlled trials with canagliflozin
Side Effect Canagliflozin
(% of patients)
Placebo
(% of patients)
UTI 8.2% 6.7%

  • Reference [6]
Placebo-controlled trials with dapagliflozin (Dap)
Side Effect Dap 5 mg
(% of patients)
Dap 10 mg
(% of patients)
Placebo
(% of patients)
UTI 5.7% 4.3% 3.7%

  • Reference [7]
Placebo-controlled trials with empagliflozin (Emp)
Side Effect Emp 10 mg
(% of patients)
Emp 25 mg
(% of patients)
Placebo
(% of patients)
UTI 7.6% 9.3% 7.6%

  • Reference [2]
Placebo-controlled trials with canagliflozin
Side Effect Canagliflozin
(% of patients)
Placebo
(% of patients)
Increased urination 4.5 - 5.5% 0.8%
Increased thirst 2 - 3% 0.2%
Constipation 1.8 - 2.3% 0.9%
Reduced vascular volume events
(hypotension, lightheadedness, etc.)
3 - 5% 2.4%

  • *Volume depletion symptoms include dehydration, hypotension, etc.
  • Reference [6]
Placebo-controlled trials with dapagliflozin (Dap)
Side Effect Dap 5 mg
(% of patients)
Dap 10 mg
(% of patients)
Placebo
(% of patients)
Increased urination 2.9% 3.8% 1.7%
Symptoms associated with
volume depletion*
0.6% 0.8% 0.4%
Constipation 2.2% 1.9% 1.5%

  • *Volume depletion symptoms include dehydration, hypotension, etc.
  • Reference [7]
Placebo-controlled trials with empagliflozin (Emp)
Side Effect Emp 10 mg
(% of patients)
Emp 25 mg
(% of patients)
Placebo
(% of patients)
Increased urination 3.4% 3.2% 1.0%
Symptoms associated with
volume depletion
0.5% 0.3% 0.3%







NOTE: Drug interactions presented here are NOT all-inclusive. Other interactions may exist. The interactions presented here are meant to encompass commonly prescribed medications and/or interactions that are well-documented. Always consult your physician or pharmacist before taking medications concurrently. CLICK HERE for more information on drug interactions.